⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure 1 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Gillian Vandekerkhove Andrew J. Murtha David C. Müller Maria Stephenson Kimia Rostin Aslı D. Munzur Carlos Vasquez-Rios Jussi Nikkola Joonatan Sipola Matti Annala Cameron Herberts Emily Fung Jaskirat Atwal Sadeem Al-Subaie Karan Parekh Cecily Q. Bernales Gráinne Donnellan Daygen L. Finch Krista Noonan Jenny J. Ko Güliz Özgün Lucia Nappi Christian Kollmannsberger Jean‐Michel Lavoie Sunil Parimi Tilman Todenhöfer Piet Ost Gang Wang Peter C. Black Corinne Maurice‐Dror Kim N.Bernhard J. Eigl Alexander W. Wyatt

View Full Paper

Ask AI

Bookmark

Share

Key Points

ERBB2 mutations and copy number amplifications were identified, highlighting potential biomarkers for treatment response.
The analysis focused on ctDNA and metastatic tissues, revealing critical insights into cancer genetics.
Findings suggest that monitoring ERBB2 alterations in ctDNA may inform therapeutic strategies.
The study emphasizes the importance of assessing genetic changes in metastatic urothelial cancer.

Implication

Observational analysis identifies ERBB2 mutations and amplifications in ctDNA and tissues, suggesting their role in cancer progression.

Abstract

Supplementary Figure 1. Identification of ERBB2 mutations and copy number amplifications.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vandekerkhove et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02acb https://doi.org/10.1158/1078-0432.30029663

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
2Supplementary Figure 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
3Supplementary Figure 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
4Supplementary Figure 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
5Supplementary Figure 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025

More related papers

Supplementary Figure 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
Supplementary Figure 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
Supplementary Figure 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025